A Retrospective Study on Hospitalized Patients With Community-acquired Pneumonia in China (CAP-China)

Community Acquired Pneumonia Clinical Trial

— RSCAP-China  

Official title:

Management in Real-life of Patients Hospitalized With Community-acquired Pneumonia in China

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT02489578
• Other study ID #: NCT20150101
• Status: Unknown status
• Phase: N/A
• First received: March 16, 2015
• Last updated: October 14, 2015
• Start date: July 2015
• Est. completion date: December 2016

Study information

• Verified date: October 2015
• Source: Capital Medical University
• Contact: Bin Cao, MD
• Phone: 86-010-84206264
• Email: caobin_ben[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and healthcare-associated pneumonia (HCAP) in real life of China .

Description:

In China, the data about current management of patients hospitalized with CAP in the real-life setting is not available,type of pneumonia, selection of initial antibiotic, time to clinical stability, antibiotic choice anf modification,clinical outcomes and costs remain unclear.

In this study, we will collect comprehensive information on CAP and HCAP management patterns to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China .to analyze microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of patients with CAP (> and = 65 years, different comorbidities ,risk factors) ,to investigate microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of disease severity with CAP ,to provide the difference on microbiological characteristics,clinical manifestations,antibiotic regimens ,and outcome between patients with CAP and HCAP ,to understand the current situation of antibiotic regimen ,to evaluate influence of different antibiotic regimens on prognosis.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 3000
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years and older

Eligibility

Inclusion Criteria:

• Patients > or = 14 years of age

• Patient meets the criteria of community acquired pneumonia

• Patient meets the criteria of healthcare-associated pneumonia

Exclusion Criteria:

• Patients <14 years of age

• Patient meets the criteria of hospital acquired pneumonia

• Known active tuberculosis or current treatment for tuberculosis

• Non-infectious pulmonary diseases

• HIV positive

Related Conditions & MeSH terms

• Community Acquired Pneumonia
• Pneumonia

Intervention

Other:
• other
retrospective cohort study

Locations

Country	Name	City	State
China	China-Japan Friendship Hospital	Beijing

Sponsors (11)

Lead Sponsor	Collaborator
Capital Medical University	Beijing Chao Yang Hospital, Beijing Huimin Hospital, Beijing Jishuitan Hospital, Beijing Luhe Hospital, China-Japan Friendship Hospital, Kunming Yan'an Hospital, Linzi Hospital, Qilu Hospital of Shandong University, Qingdao Municipal Hospital, Second Hospital of Beijing Armed Police Corps

Country where clinical trial is conducted

China, 

References & Publications (3)

Cao B, Huang GH, Pu ZH, Qu JX, Yu XM, Zhu Z, Dong JP, Gao Y, Zhang YX, Li XH, Liu JH, Wang H, Xu Q, Li H, Xu W, Wang C. Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia. Chest. 2014 Jan;145(1):79-86. doi: 10.1378/ — View Citation

Qu J, Gu L, Wu J, Dong J, Pu Z, Gao Y, Hu M, Zhang Y, Gao F, Cao B, Wang C; Beijing Network for Adult Community-Acquired Pneumonia (BNACAP). Accuracy of IgM antibody testing, FQ-PCR and culture in laboratory diagnosis of acute infection by Mycoplasma pneu — View Citation

Yang SQ, Qu JX, Wang C, Yu XM, Liu YM, Cao B. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period. Clin Respir J. 2014 Apr;8(2):185-91. doi: 10.1111/crj.12056. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	treatment failure at 72h after initiation of antibiotics	treatment failure was defined as a change of antibiotics due to worsening signs or symptoms associated with pneumonia	Time from the first dose use of antibiotics to 72 hours
Primary	in-hospital treatment failure due to multiple causes	1)death in hospital;2)change of antibiotics due to worsening signs or symptoms of infection, 3) recurrence, defined as signs or symptoms of infection after completion of therapy requiring re-initiation of antibiotics	Time from date of admission to discharge up to 1 week
Secondary	Duration of intravenous antimicrobial therapy	Time from the first dose of intravenous antibiotics to date of stop of intravenous antibiotics ,participants will be followed for the duration of hospital stay	2 weeks
Secondary	Hospital length of stay	Patients will be asked about hospitalization, date, Patients will be asked about hospitalization, date, participants will be asked about the time of admission and discharge	2 weeks
Secondary	in-hospital mortality	Time from date of admission to date of discharge,participants will be followed for the duration of hospital stay	2 weeks

External Links

•   Link
•   Link
•   Link